Biotech Stock News (CMRX) (PTCT) (SRPT) (BMRN) (PPHM)

Chimerix (NASDAQ:CMRX)  On Monday February 22, 2016 shares of Chimerix tumbled by 40% as the company announced that two phase 3 trials had to be stopped because of lack of efficacy. The phase 3 trial, known as the SUPPRESS trial, recruited a total of 452 patients. The patients that were recruited in the trial were … Read more